A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in ...

A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.

Erythropoietin, the protein that drives red blood cell formation, also induces tolerance in dendritic cells, leading to the ...

CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...

Over time, clonal expansion leads to an increase in the frequency of infected cells in a patient. The proviruses in daughter ...

In multiple myeloma, plasma cells proliferate uncontrollably in the bone marrow, disrupting the growth of healthy ...

Discover why CLLS is a top speculative Buy, with promising CAR-T therapies, strong big pharma partnerships, and attractive ...

Human intestinal M cells function as dendritic cell-like antigen-presenting cells, displaying constitutive MHC-II activity ...